Fried Frank acted as counsel to Goldman Sachs as financial advisor to Biogen in its approximately US$800 million acquisition of Nightstar Therapeutics. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Nightstar Therapeutics is a clinical-stage gene therapy company focused on developing and commercializing novel, one-time treatments for patients suffering from rare inherited retinal diseases. The transaction is expected to close by mid-2019.
The Fried Frank team was led by corporate partner Philip Richter and included corporate associate Meka Jegede.